The 23 references in paper G. Berezovskaya A., N. Petrischev N., L. Papayan P., M. Karpenko A., O. Smirnova A., T. Lazovskaya V., O. Napalkova S., Г. БЕРЕЗОВСКАЯ А., Н. ПЕТРИЩЕВ Н., Л. ПАПАЯН П., М. КАРПЕНКО А., О. СМИРНОВА А., Т. ЛАЗОВСКАЯ В., О. НАПАЛКОВА С. (2015) “ИНТЕНСИВНОСТЬ ОБРАЗОВАНИЯ ТРОМБИНА У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА ПОСЛЕ КОРОНАРНОГО СТЕНТИРОВАНИЯ // THE INTENSITY OF THROMBIN FORMATION IN PATIENTS WITH CORONARY HEART DISEASE AFTER CORONARY STENTING” / spz:neicon:aterotromboz:y:2015:i:2:p:115-123

1
Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost,2013. 11 Suppl 1: 242-53.
(check this in PDF content)
2
Mannucci PM, Franchini M. The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism. Expert Rev Hematol, 2014. 7(6): 757–65.
(check this in PDF content)
3
Наместников Ю.А., Матвиенко О.Ю., Головина О.Г., Хаит Е.А, Николаева А.Е., Папаян Л.П. Тест генерации — условия постановки теста для выявления состояний гиперкоагуляции. Клиническая лабораторная диагностика, 2011. 7: 35–38.
(check this in PDF content)
4
Tanalp AC, Oduncu V, Erkol A, Go..zo..bu..yu..k G, Ozveren O, DЯndar C et al. Soluble endothelial protein C receptor levels and protein C activity in patients with acute ST-segment elevation myocardial infarction. Coron Artery Dis, 2013. 24(3): 209–16.
(check this in PDF content)
5
Goel PK, Batra A. Protein C and/or protein S deficiency and occurrence of stent thrombosis: a hitherto unrecognized association. J Interv Cardiol, 2010. 6. 23(6): 560-4.
(check this in PDF content)
6
Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb,2003. 33: 4–15.
(check this in PDF content)
7
Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/- thrombomodulin to recognize the prothrombotic phenotype. Thromb. Haemost., 2006. 96(5): 562–567.
(check this in PDF content)
8
Tripodi A, Martinelli I, Chantarangkul V, Battaglioli T, Clerici M, Mannucci PM. The endogenous thrombin potential and the risk of venous thromboembolism. Thromb. Res., 2007. 121: 353–359.
(check this in PDF content)
9
Liesel S, Sandset PM, Mowinckel MC, Wisloff F. Activated protein С resistance determined with a thrombin generationbased test is associated with thrombotic events in patients with lupus anticoagulants. J. Thromb. Haemost.,2007. 5(11): 2204–10.
(check this in PDF content)
10
Schuliga M. The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease. Mediators Inflamm., 2015. 2015: 437695.
(check this in PDF content)
11
Баркаган З.С., Котовщикова Е.Ф., Цывкина Л.П., Мамаев А.Н. Влияние тиенопиридиновых антиагрегантов на тромбоцитарное, коагулянтное и антикоагулянтное звенья гемостаза при лечении тpoмбoзoв и тромбофилий. Тромбоз, гемостаз и реология, 2005. 3: 10–15.
(check this in PDF content)
12
Awtry EH, Loscalzo J. Aspirin. Circulation, 2000. 14. 101(10): 1206–18.
(check this in PDF content)
13
Bratseth V, Pettersen AA, Opstad TB, Arnesen H, Seljeflot I. Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment. Thromb J., 2012. 10(1): 12.
(check this in PDF content)
14
Mitchell CT, Kamineni A, Palmas W, Cushman M. Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2009. 207(1): 277–83.
(check this in PDF content)
15
Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulya’k K, Ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost, 2008. 6(1): 125–31.
(check this in PDF content)
16
Borissoff J.I., Spronk H.M., ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med, 2011. 5. 364(18): 1746–60.
(check this in PDF content)
17
Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets, 2010. 21(5): 360–7.
(check this in PDF content)
18
Walderveen MC, Berry LR, Atkinson HM, Chan AK. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va. Thromb Haemost, 2010. 103(5): 910–9.
(check this in PDF content)
19
Березовская Г.А., Смирнова О.А., Петрищев Н.Н., Папаян Л.П., Карпенко М.А., Головина О.Г., Хромов-Борисов Н.Н. Тест генерации тромбина в оценке действия антиагрегантов у больных ишемической болезнью сердца после чрескожного коронарного вмешательства. Атеротромбоз, 2015. 1: 40–50.
(check this in PDF content)
20
Lee K, Kim JE, Kwon J, Kim I, Yoon SS, Park S et al. Poor prognosis of hypocoagulability assessed by thrombin generation assay in disseminated intravascular coagulation. Blood Coagul Fibrinolysis,2014. 25(3): 241–7.
(check this in PDF content)
21
Dahlback B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol,2005. 25: 1311–20.
(check this in PDF content)
22
Weiler H. Regulation of inflammation by the protein C system. Crit Care Med, 2010. 38: S18–25.
(check this in PDF content)
23
Rezaie AR. Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem. 2010. 17: 2059–69.
(check this in PDF content)